

Krebs Biochemicals & Industries Limited

8-2-577/B, Plot No. 34, 3rd Floor, Maas Heights, Road No. 8, Banjara Hills, Hyderabad-500 034

CIN : L24110TG1991PLCO13511



13th August, 2015

To,
The Manager,
Department of Corporate Relations,
BSE Limited,
P J Towers, Dalal Street,
Fort, Mumbai- 400001.

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai- 400051.

Dear Sir/Madam,

Sub: Submission of Unaudited Financial Results for the quarter ended 30th June 2015..

Ref: Clause 41 of the Listing Agreement


We refer to the above mentioned subject, we herewith submit the Exchange the unaudited financial results and the Limited Review Report for the quarter ended 30th June, 2015 as required under Clause 41 of the Listing Agreement.

This is for the information and records of the Exchange, Please.

Thanking You,

Yours Faithfully,

For Krebs Biochemicals & Industries Limited


Haritha Varanasi
Company Secretary



Encl. as above.

STAND ALONE FINANCIAL RESULTS FOR THE QUARTER / PERIOD ENDED 30TH JUNE, 2015

(Rs. In lacs)

		Quarter Ended			Previous Year Ended (6 Months)
		30.06.2015 (Unaudited)	31.03.2015 (Audited)	30.06.2014 (Unaudited)	31.03.2015 (Audited)
	PART - 1				
1	Income from Operations				
	a) Net Sales / Income from Operations (Net of Excise Duty)	15.85	-	-	-
	b) Other Operating Income	-	-	-	-
	Total Income from operations (net)	15.85	-	-	-
2	Expenses				
	a. Cost of Material Consumed	13.22	-	-	0.00
	b. Changes in inventories of finished goods, work-in-progress and stock -in-trade	(2.75)	-	-	-
	c. Employee benefits expense	138.53	117.74	10.27	185.68
	d. Depreciation and Amortisation expense	95.54	187.13	-	187.13
	e. Other Expenses	178.17	232.71	56.80	304.57
	Total Expenses	422.71	537.58	67.07	677.38
3	Profit / (Loss) from Operations before other income, finance costs and exceptional items (1 - 2)	(406.86)	(537.58)	(67.07)	(677.38)
4	Other Income	0.75	1.12	319.08	1.12
5	Profit / (Loss) from ordinary activities before finance costs (3 ± 4)	(406.11)	(536.46)	252.01	(676.26)
6	Finance Costs	0.19	402.60	0.71	402.85
7	Profit / (Loss) from Ordinary Activities before tax (5 ± 6)	(406.30)	(939.06)	251.30	(1,079.11)
8	Exceptional Items:				
	a) Debit balances written off	-	(692.16)	-	(692.16)
	b) Waiver of Principal of Bank Loans & Others	-	3,625.17	-	3,625.17
	c) Depletion in Value of Inventory	-	(2,637.91)	-	(2,637.91)
	d) Amounts Written Back	52.03	-	-	-
	e) Profit on Sale of Food Division's Immovables	59.12	-	-	-
9	Net Profit / (Loss) for the period (7 ± 8)	(295.15)	(643.96)	251.30	(784.01)
10	Tax Expense	-	-	-	-
11	Net Profit / (Loss) from ordinary activities after Tax (9 ± 10)	(295.15)	(643.96)	251.30	(784.01)
12	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	1241.43	951.43	951.43	951.43
13	Earning Per Share (not annualised for the quarter)				
	(a) Basic	(2.38)	(6.77)	2.64	(8.24)
	(b) Diluted	(2.38)	(6.77)	2.64	(8.24)
	PART - 2				
A	PARTICULARS OF SHAREHOLDING				
1	Public Share Holding				
	- Number of Shares	5,529,646	6,716,146	4,766,146	6,716,146
	- Percentage of Shareholding	44.54%	70.59%	50.10%	70.59%
2	Promoter and Promoter Group Shareholding				
	a) Pledged / Encumbered				
	- Number of Shares	2,208,400	2,208,400	4,261,724	2,208,400
	- Percentage of Shareholding (as a % of the total shareholding of promoter and promoter group)	32.08%	78.92%	89.76%	78.92%
	- Percentage of Shares (as a % of total share capital of the Company)	17.79%	23.21%	44.79%	23.21%
	b) Non - Pledged / Encumbered				
	- Number of Shares	4,676,240	589,740	486,416	589,740
	- Percentage of Shares (as a % of total shareholding of promoter and promoters group)	67.92%	21.08%	10.24%	21.08%
	- Percentage of Shares (as a % of total share capital of the Company)	37.67%	6.20%	5.11%	6.20%

PARTICULARS

B	INVESTOR COMPLAINTS	
1	PENDING AT THE BEGINNING OF THE QUARTER	NIL
2	RECEIVED DURING THE QUARTER	1
3	DISPOSED OFF DURING THE QUARTER	0
4	REMAINING UNRESOLVED AT THE END OF THE QUARTER	1

1	The above results have been reviewed by the Audit Committee at its meeting held on 13th Aug, 2015 and approved by the Board of Directors of the Company at its meeting held on 13th Aug, 2015.
2	The Above results are subjected to limited review by Company's Statutory Auditors.
3	The Unit-II located at Vizag has started operations from April 2015.
4	The Company is operating in one segment only hence no segment results have been disclosed.
5	Figures have been regrouped, rearranged wherever necessary.

Place - Hyderabad

Date - 13.08.2015


 Avinash Ravi
 Managing Director



PAVULURI & Co.

CHARTERED ACCOUNTANTS

105, 1st Block, 1st Floor, Divya Shakti Complex,

Ameerpet, Hyderabad - 500 016.

Ph : 040 - 2373 1837, 4025 8691

Fax : 040 - 2374 8729

Email : pavulurilandco@gmail.com

pavulurilandco@hotmail.com

Review Report to the Board of Directors of Krebs Biochemicals & Industries Limited

We have reviewed the accompanying statement of unaudited financial results of **M/s. Krebs Biochemicals & Industries Limited** ("the company") for the quarter 30th June, 2015 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial Information performed by the independent Auditor of Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results for the Quarter ended 30th June 2015 prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad

Date: 13.08.2015

For PAVULURI & Co.
Chartered Accountants
Firm Regn. No: 012194S


(CA. N. RAJESH)
PARTNER
M.No: 223169

